Abstract
Several small molecule effectors of myosin function that target the motor domains of myosin classes I, II, V, and VI have been identified. Four distinct binding sites in the myosin motor domain have been reported with unique properties and mechanisms of action. This chapter describes the structural basis and activities of known small molecule effectors that allosterically target the myosin motor domain.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allingham JS, Smith R, Rayment I (2005) The structural basis of blebbistatin inhibition and specificity for myosin II. Nat Struct Mol Biol 12:378–379. https://doi.org/10.1038/nsmb908
Ampe C, Van Troys M (2017) Mammalian actins: isoform-specific functions and diseases. Handb Exp Pharmacol 235:1–37. https://doi.org/10.1007/164_2016_43
Anderson RL, Trivedi DV, Sarkar SS et al (2018) Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci 115:E8143–E8152. https://doi.org/10.1073/PNAS.1809540115
Behrens VA, Münnich S, Adler-Gunzelmann G et al (2017) The conserved lysine-265 allosterically modulates nucleotide- and actin-binding site coupling in myosin-2. Sci Rep 7:7650. https://doi.org/10.1038/s41598-017-07933-y
Behrmann E, Müller M, Penczek PA et al (2012) Structure of the rigor actin-tropomyosin-myosin complex. Cell 150:327–338. https://doi.org/10.1016/J.CELL.2012.05.037
Beier N, Harting J, Jonas R et al (1991) The novel cardiotonic agent EMD 53 998 is a potent “calcium sensitizer”. J Cardiovasc Pharmacol 18:17–27
Berg JS, Powell BC, Cheney RE (2001) A millennial myosin census. Mol Biol Cell 12:780–794. https://doi.org/10.1091/mbc.12.4.780
Brandstaetter H, Kishi-Itakura C, Tumbarello DA et al (2014) Loss of functional MYO1C/myosin 1c, a motor protein involved in lipid raft trafficking, disrupts autophagosome-lysosome fusion. Autophagy 10:2310–2323. https://doi.org/10.4161/15548627.2014.984272
Bryce NS, Schevzov G, Ferguson V et al (2003) Specification of actin filament function and molecular composition by tropomyosin isoforms. Mol Biol Cell 14:1002–1016. https://doi.org/10.1091/mbc.e02-04-0244
Chabaud M, Heuzé ML, Bretou M et al (2015) Cell migration and antigen capture are antagonistic processes coupled by myosin II in dendritic cells. Nat Commun 6:7526. https://doi.org/10.1038/ncomms8526
Charlton MR, Balagopal P, Nair KS (1997) Skeletal muscle myosin heavy chain synthesis in type 1 diabetes. Diabetes 46:1336–1340. https://doi.org/10.2337/diab.46.8.1336
Cheung A, Dantzig JA, Hollingworth S et al (2002) A small-molecule inhibitor of skeletal muscle myosin II. Nat Cell Biol 4:83–88. https://doi.org/10.1038/ncb734
Chinthalapudi K, Taft MH, Martin R et al (2011) Mechanism and specificity of pentachloropseudilin-mediated inhibition of myosin motor activity. J Biol Chem 286:29700–29708. https://doi.org/10.1074/jbc.M111.239210
Chinthalapudi K, Heissler SM, Preller M et al (2017) Mechanistic insights into the active site and allosteric communication pathways in human nonmuscle myosin-2C. Elife 6:1–24. https://doi.org/10.7554/eLife.32742
Cohen P, Alessi DR (2013) Kinase drug discovery – what’s next in the field? ACS Chem Biol 8:96–104. https://doi.org/10.1021/cb300610s
Coulton AT, East DA, Galinska-Rakoczy A et al (2010) The recruitment of acetylated and unacetylated tropomyosin to distinct actin polymers permits the discrete regulation of specific myosins in fission yeast. J Cell Sci 123:3235–3243. https://doi.org/10.1242/JCS.069971
Cowman AF, Tonkin CJ, Tham WH, Duraisingh MT (2017) The molecular basis of erythrocyte invasion by malaria parasites. Cell Host Microbe 22:232–245. https://doi.org/10.1016/j.chom.2017.07.003
Cramer LP, Mitchison TJ (1995) Myosin is involved in postmitotic cell spreading. J Cell Biol 131:179–189. https://doi.org/10.1083/jcb.131.1.179
Cymerys J, SŁonska A, Skwarska J, Banbura MW (2016) Function of myosin during entry and egress of equid herpesvirus type 1 in primary murine neurons. Acta Virol 60:410–416. https://doi.org/10.4149/av_2016_04_410
Dos Remedios CG, Chhabra D, Kekic M et al (2003) Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 83:433–473. https://doi.org/10.1152/physrev.00026.2002
Dunn TA, Chen S, Faith DA et al (2006) A novel role of myosin VI in human prostate cancer. Am J Pathol 169:1843–1854. https://doi.org/10.2353/AJPATH.2006.060316
Fedorov R, Böhl M, Tsiavaliaris G et al (2009) The mechanism of pentabromopseudilin inhibition of myosin motor activity. Nat Struct Mol Biol 16:80–88. https://doi.org/10.1038/nsmb.1542
Ferreira G, Artigas P, Pizarro Gustavo Brum G (1997) Butanedione Monoxime promotes voltage-dependent inactivation of L-type calcium channels in heart. Effects on gating currents. J Mol Cell Cardiol 29:777–787. https://doi.org/10.1006/JMCC.1996.0321
Ferroni C, Hano O, Ventura C et al (1991) A novel positive inotropic substance enhances contractility without increasing the Ca2+ transient in rat myocardium. J Mol Cell Cardiol 23:325–331. https://doi.org/10.1016/0022-2828(91)90068-W
Fischer S, Windshügel B, Horak D et al (2005) Structural mechanism of the recovery stroke in the myosin molecular motor. Proc Natl Acad Sci U S A 102:6873–6878. https://doi.org/10.1073/pnas.0408784102
Foth BJ, Goedecke MC, Soldati D (2006) New insights into myosin evolution and classification. Proc Natl Acad Sci 103:3681–3686. https://doi.org/10.1073/pnas.0506307103
Galińska-Rakoczy A, Engel P, Xu C et al (2008) Structural basis for the regulation of muscle contraction by troponin and tropomyosin. J Mol Biol 379:929–935. https://doi.org/10.1016/J.JMB.2008.04.062
Gambassi G, Capogrossi MC, Klockow M, Lakatta EG (1993) Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. Am J Physiol 264:H728–H738. https://doi.org/10.1152/ajpheart.1993.264.3.H728
Gateva G, Kremneva E, Reindl T et al (2017) Tropomyosin isoforms specify functionally distinct actin filament populations in vitro. Curr Biol 27:705–713. https://doi.org/10.1016/J.CUB.2017.01.018
Geeves MA, Fedorov R, Manstein DJ (2005) Molecular mechanism of actomyosin-based motility. Cell Mol Life Sci 62:1462–1477. https://doi.org/10.1007/s00018-005-5015-5
Goebel HH, Laing NG (2009) Actinopathies and myosinopathies: Mini-symposium: Protein aggregate myopathies. Brain Pathol 19:516–522. https://doi.org/10.1111/j.1750-3639.2009.00287.x
Green EM, Wakimoto H, Anderson RL et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351:617–621. https://doi.org/10.1126/science.aad3456
Greenberg B (2016) Novel therapies for heart failure – where do they stand? Circ J 80:1882–1891. https://doi.org/10.1253/circj.CJ-16-0742
Gunning PW, Hardeman EC, Lappalainen P, Mulvihill DP (2015) Tropomyosin – master regulator of actin filament function in the cytoskeleton. J Cell Sci 128:2965–2974. https://doi.org/10.1242/jcs.172502
Gupta P, Martin R, Knölker H-J et al (2017) Myosin-1 inhibition by PClP affects membrane shape, cortical actin distribution and lipid droplet dynamics in early Zebrafish embryos. PLoS One 12:e0180301. https://doi.org/10.1371/journal.pone.0180301
Heissler SM, Selvadurai J, Bond LM et al (2012) Kinetic properties and small-molecule inhibition of human myosin-6. FEBS Lett 586:3208–3214. https://doi.org/10.1016/j.febslet.2012.07.014
Herrmann C, Wray J, Travers F, Barman T (1992) Effect of 2,3-butanedione monoxime on myosin and myofibrillar ATPases. An example of an uncompetitive inhibitor. Biochemistry 31:12227–12232. https://doi.org/10.1021/bi00163a036
Higuchi H, Takemori S (1989) Butanedione monoxime suppresses contraction and ATPase activity of rabbit skeletal muscle. J Biochem 105:638–643. https://doi.org/10.1093/oxfordjournals.jbchem.a122717
Hiratsuk T (1994) Nucleotide-induced closure of the ATP-binding pocket in myosin subfragment-1. J Biol Chem 269:27251–27257
Hiratsuka T (2006) The interaction of Phe472 with a fluorescent inhibitor bound to the complex of myosin subfragment-1 with nucleotide. Biochemistry 45:1234–1241. https://doi.org/10.1021/bi051373l
Hou Y-P, Qu X-P, Mao X-W et al (2018) Resistance mechanism of Fusarium fujikuroi to phenamacril in the field. Pest Manag Sci 74:607–616. https://doi.org/10.1002/ps.4742
Houdusse A, Sweeney HL (2016) How myosin generates force on actin filaments. Trends Biochem Sci 41:989–997
Hundt N, Steffen W, Pathan-Chhatbar S et al (2016) Load-dependent modulation of non-muscle myosin-2A function by tropomyosin 4.2. Sci Rep 6:20554. https://doi.org/10.1038/srep20554
Hur E-M, Yang IH, Kim D-H et al (2011) Engineering neuronal growth cones to promote axon regeneration over inhibitory molecules. Proc Natl Acad Sci U S A 108:5057–5062. https://doi.org/10.1073/pnas.1011258108
Islam K, Chin HF, Olivares AO et al (2010) A myosin V inhibitor based on privileged chemical scaffolds. Angew Chem Int Ed 49:8484–8488. https://doi.org/10.1002/anie.201004026
Kaplinsky E, Mallarkey G (2018) Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs Context 7:1–10. https://doi.org/10.7573/dic.212518
Kawas RF, Anderson RL, Bartholomew Ingle SR et al (2017) A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem 292:16571–16577. https://doi.org/10.1074/jbc.M117.776815
Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71–78. https://doi.org/10.1038/nrd1609
Képiró M, Várkuti BH, Végner L et al (2014) para-nitroblebbistatin, the non-cytotoxic and photostable myosin II inhibitor. Angew Chem Int Ed 53:8211–8215. https://doi.org/10.1002/anie.201403540
Kintses B, Yang Z, Málnási-Csizmadia A (2008) Experimental investigation of the seesaw mechanism of the relay region that moves the myosin lever arm. J Biol Chem 283:34121–34128. https://doi.org/10.1074/jbc.M805848200
Kollmar M, Mühlhausen S (2017) Myosin repertoire expansion coincides with eukaryotic diversification in the Mesoproterozoic era. BMC Evol Biol 17:211. https://doi.org/10.1186/s12862-017-1056-2
Kovács M, Tóth J, Hetényi C et al (2004) Mechanism of blebbistatin inhibition of myosin II. J Biol Chem 279:35557–35563. https://doi.org/10.1074/jbc.M405319200
Lehrer SS, Morris EP (1982) Dual effects of tropomyosin and troponin-tropomyosin on actomyosin subfragment 1 ATPase. J Biol Chem 257:8073–8080
Lehrer SS, Morris EP (1984) Comparison of the effects of smooth and skeletal tropomyosin on skeletal actomyosin subfragment 1 ATPase. J Biol Chem 259:2070–2072
Li H, Diao Y, Wang J et al (2008) JS399-19, a new fungicide against wheat scab. Crop Prot 27:90–95. https://doi.org/10.1016/J.CROPRO.2007.04.010
Li M, Ogilvie H, Ochala J, Artemenko K, Iwamoto H, Yagi N, Bergquist J, Larsson L (2015) Aberrant post-translational modifications compromise human myosin motor function in old age. Aging Cell 14:228–235. https://doi.org/10.1111/acel.12307
Li B, Zheng Z, Liu X et al (2016a) Genotypes and characteristics of phenamacril-resistant mutants in Fusarium asiaticum. Plant Dis 100:1754–1761. https://doi.org/10.1094/PDIS-02-16-0169-RE
Li Y-R, Yang W-X, Li Y-R, Yang W-X (2016b) Myosins as fundamental components during tumorigenesis: diverse and indispensable. Oncotarget 7:46785–46812. https://doi.org/10.18632/oncotarget.8800
Limouze J, Straight AF, Mitchison T, Sellers JR (2004) Specificity of blebbistatin, an inhibitor of myosin II. J Muscle Res Cell Motil 25:337–341. https://doi.org/10.1007/s10974-004-6060-7
Liu Y, White HD, Belknap B et al (2015) Omecamtiv mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin. Biochemistry 54:1963–1975. https://doi.org/10.1021/bi5015166
Lopatin AN, Nichols CG (1993) Block of delayed rectifier (DRK1) K+ channels by internal 2,3-butanedione monoxime in Xenopus oocytes. Receptors Channels 1:279–286
Lucas-Lopez C, Allingham JS, Lebl T et al (2008) The small molecule tool (S)-(−)-blebbistatin: novel insights of relevance to myosin inhibitor design. Org Biomol Chem 6:2076. https://doi.org/10.1039/b801223g
Lymn RW, Taylor EW (1971) Mechanism of adenosine triphosphate hydrolysis by actomyosin. Biochemistry 10:4617–4624. https://doi.org/10.1021/bi00801a004
Ma X, Adelstein RS (2014) The role of vertebrate nonmuscle myosin II in development and human disease. BioArchitecture 4:88–102. https://doi.org/10.4161/bioa.29766
Malik FI, Hartman JJ, Elias KA et al (2011) Cardiac myosin activation: A potential therapeutic approach for systolic heart failure. Science 331:1439–1443. https://doi.org/10.1126/science.1200113
Manstein DJ, Mulvihill DP (2016) Tropomyosin-mediated regulation of cytoplasmic myosins. Traffic 17:872–877. https://doi.org/10.1111/tra.12399
Manstein DJ, Meiring JCM, Hardeman EC, Gunning PW (2019) Actin–tropomyosin distribution in non-muscle cells. J Muscle Res Cell Motil:1–12. https://doi.org/10.1007/s10974-019-09514-0
Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy. Circ Res 121:749–770. https://doi.org/10.1161/CIRCRESAHA.117.311059
Martin R, Risacher C, Barthel A et al (2014) Silver(I)-catalyzed route to pyrroles: synthesis of halogenated pseudilins as allosteric inhibitors for myosin atpase and x-ray crystal structures of the protein-inhibitor complexes. European J Org Chem 2014:4487–4505. https://doi.org/10.1002/ejoc.201402177
Mckillop DFA, Fortune NS, Ranatunga KW, Geeves MA (1994) The influence of 2,3-butanedione 2-monoxime (BDM) on the interaction between actin and myosin in solution and in skinned muscle fibres. J Muscle Res Cell Motil 15:309–318. https://doi.org/10.1007/BF00123483
Meiring JCM, Bryce NS, Wang Y et al (2018) Co-polymers of actin and tropomyosin account for a major fraction of the human actin cytoskeleton. Curr Biol 28:2331–2337.e5. https://doi.org/10.1016/j.cub.2018.05.053
Melchionda S, Ahituv N, Bisceglia L et al (2001) MYO6, the human homologue of the gene responsible for deafness in Snell’s waltzer mice, is mutated in autosomal dominant nonsyndromic hearing loss. Am J Hum Genet 69:635–640. https://doi.org/10.1086/323156
Mohiddin SA, Ahmed ZM, Griffith AJ et al (2004) Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6). J Med Genet 41:309–314. https://doi.org/10.1136/jmg.2003.011973
Moore JR, Campbell SG, Lehman W (2016) Structural determinants of muscle thin filament cooperativity. Arch Biochem Biophys 594:8–17. https://doi.org/10.1016/j.abb.2016.02.016
Moraczewska J, Nicholson-Flynn K, Hitchcock-DeGregori SE (1999) The ends of tropomyosin are major determinants of actin affinity and myosin subfragment 1-induced binding to F-actin in the open state. Biochemistry 38:15885–15892. https://doi.org/10.1021/bi991816j
Morgan BP, Muci A, Lu PP et al (2010) Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett 1:472–477. https://doi.org/10.1021/ml100138q
Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523–6543. https://doi.org/10.1021/JM058225D
Münnich S, Pathan-Chhatbar S, Manstein DJ (2014a) Crystal structure of the rigor-like human non-muscle myosin-2 motor domain. FEBS Lett 588:4754–4760. https://doi.org/10.1016/j.febslet.2014.11.007
Münnich S, Taft MH, Manstein DJ (2014b) Crystal structure of human myosin 1c—the motor in GLUT4 exocytosis: implications for Ca2+ regulation and 14-3-3 binding. J Mol Biol 426:2070–2081. https://doi.org/10.1016/j.jmb.2014.03.004
Murphy CT, Spudich JA (1999) The sequence of the myosin 50−20K loop affects myosin’s affinity for actin throughout the actin−myosin ATPase cycle and its maximum ATPase activity. Biochemistry 38:3785–3792. https://doi.org/10.1021/BI9826815
Nadif Kasri N, Van Aelst L (2008) Rho-linked genes and neurological disorders. Pflügers Arch – Eur J Physiol 455:787–797. https://doi.org/10.1007/s00424-007-0385-1
Odronitz F, Kollmar M (2007) Drawing the tree of eukaryotic life based on the analysis of 2,269 manually annotated myosins from 328 species. Genome Biol 8:R196. https://doi.org/10.1186/gb-2007-8-9-r196
Ohri RV, Radosevich AT, James Hrovat K et al (2005) A Re(V)-catalyzed C−N bond-forming route to human lipoxygenase inhibitors. Org Lett 7:2501. https://doi.org/10.1021/OL050897A
Ostap EM (2002) 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil 23:305–308. https://doi.org/10.1023/A:1022047102064
Papadaki M, Holewinski RJ, Previs SB et al (2018) Diabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function. JCI Insight 3. https://doi.org/10.1172/JCI.INSIGHT.121264
Patel H, Margossian SS, Chantler PD (2000) Locking regulatory myosin in the off-state with trifluoperazine. J Biol Chem 275:4880–4888. https://doi.org/10.1074/jbc.275.7.4880
Pathan-Chhatbar S, Taft MH, Reindl T et al (2018) Three mammalian tropomyosin isoforms have different regulatory effects on nonmuscle myosin-2B and filamentous β-actin in vitro. J Biol Chem 293:863–875. https://doi.org/10.1074/jbc.M117.806521
Peters U, Cherian J, Kim JH et al (2006) Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2:618–626. https://doi.org/10.1038/nchembio826
Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J et al (2017) Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun 8:190. https://doi.org/10.1038/s41467-017-00176-5
Preller M, Holmes KC (2013) The myosin start-of-power stroke state and how actin binding drives the power stroke. Cytoskeleton 70:651–660. https://doi.org/10.1002/cm.21125
Preller M, Manstein DJ (2017) Myosin motors: structural aspects and functionality. In: Reference module in life sciences
Preller M, Bauer S, Adamek N et al (2011a) Structural basis for the allosteric interference of myosin function by reactive thiol region mutations G680A and G680V. J Biol Chem 286:35051–35060. https://doi.org/10.1074/jbc.M111.265298
Preller M, Chinthalapudi K, Martin R et al (2011b) Inhibition of myosin ATPase activity by halogenated pseudilins: A structure-activity study. J Med Chem 54:3675–3685. https://doi.org/10.1021/jm200259f
Radke MB, Taft MH, Stapel B et al (2014) Small molecule-mediated refolding and activation of myosin motor function. Elife 2014:1–19. https://doi.org/10.7554/eLife.01603
Ramamurthy B, Yengo CM, Straight AF et al (2004) Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIB. Biochemistry 43:14832–14839. https://doi.org/10.1021/BI0490284
Ramsay RR, Popovic-Nikolic MR, Nikolic K et al (2018) A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7:3. https://doi.org/10.1186/s40169-017-0181-2
Rauscher AÁ, Gyimesi M, Kovács M, Málnási-Csizmadia A (2018) Targeting myosin by blebbistatin derivatives: optimization and pharmacological potential. Trends Biochem Sci 43:700–713. https://doi.org/10.1016/J.TIBS.2018.06.006
Richard P, Charron P, Carrier L et al (2003) Hypertrophic cardiomyopathy. Circulation 107:2227–2232. https://doi.org/10.1161/01.CIR.0000066323.15244.54
Rohde JA, Roopnarine O, Thomas DD, Muretta JM (2018) Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc Natl Acad Sci U S A 115:E7486–E7494. https://doi.org/10.1073/pnas.1720342115
Roman BI, Verhasselt S, Stevens CV (2018) Medicinal chemistry and use of myosin II inhibitor (S)-blebbistatin and its derivatives. J Med Chem 61:9410–9428. https://doi.org/10.1021/acs.jmedchem.8b00503
Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353–359. https://doi.org/10.1038/nrd1346
Rozbicki E, Chuai M, Karjalainen AI et al (2015) Myosin-II-mediated cell shape changes and cell intercalation contribute to primitive streak formation. Nat Cell Biol 17:397–408. https://doi.org/10.1038/ncb3138
Schaub MC, Ermini M (1969) Effect of bivalent cations on the adenosine triphosphatase of actomyosin and its modification by tropomyosin and troponin. Biochem J 111:777–783. https://doi.org/10.1042/bj1110777
Schlichter LC, Pahapill PA, Chung I (1992) Dual action of 2,3-butanedione monoxime (BDM) on K+ current in human T lymphocytes. J Pharmacol Exp Ther 261
Sellers JR, Wang F, Chantler PD (2003) Trifluoperazine inhibits the MgATPase activity and in vitro motility of conventional and unconventional myosins. J Muscle Res Cell Motil 24:579–585. https://doi.org/10.1023/B:JURE.0000009969.04562.58
Sellin LC, McArdle JJ (1994) Multiple effects of 2,3-butanedione monoxime. Pharmacol Toxicol 74:305–313. https://doi.org/10.1111/j.1600-0773.1994.tb01365.x
Senzaki H, Isoda T, Paolocci N et al (2000) Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. Circulation 101:1040–1048. https://doi.org/10.1161/01.CIR.101.9.1040
Shaw MA, Ostap EM, Goldman YE (2003) Mechanism of inhibition of skeletal muscle actomyosin by N-benzyl-p-toluenesulfonamide. Biochemistry 42:6128–6135. https://doi.org/10.1021/BI026964F
Siegman MJ, Mooers SU, Warren TB et al (1994) Comparison of the effects of 2,3-butanedione monoxime on force production, myosin light chain phosphorylation and chemical energy usage in intact and permeabilized smooth and skeletal muscles. J Muscle Res Cell Motil 15:457–472. https://doi.org/10.1007/BF00122119
Sirigu S, Hartman JJ, Planelles-Herrero VJ et al (2016) Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc Natl Acad Sci 201609342. https://doi.org/10.1073/pnas.1609342113
Solaro RJ, Gambassi G, Warshaw DM et al (1993) Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 73:981–990. https://doi.org/10.1161/01.RES.73.6.981
Spudich JA (2014) Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J 106:1236–1249. https://doi.org/10.1016/J.BPJ.2014.02.011
Stapleton MT, Fuchsbauer CM, Allshire AP (1998) BDM drives protein dephosphorylation and inhibits adenine nucleotide exchange in cardiomyocytes. Am J Physiol Circ Physiol 275:H1260–H1266. https://doi.org/10.1152/ajpheart.1998.275.4.H1260
Stern JA, Markova S, Ueda Y et al (2016) A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS One 11:e0168407. https://doi.org/10.1371/journal.pone.0168407
Straight AF, Cheung A, Limouze J et al (2003) Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 299:1743–1747. https://doi.org/10.1126/science.1081412
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480. https://doi.org/10.1038/nrc2394
Swenson AM, Tang W, Blair CA et al (2017) Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle. J Biol Chem 292:3768–3778. https://doi.org/10.1074/jbc.M116.748780
Swift LM, Asfour H, Posnack NG et al (2012) Properties of blebbistatin for cardiac optical mapping and other imaging applications. Pflügers Arch – Eur J Physiol 464:503–512. https://doi.org/10.1007/s00424-012-1147-2
Takács B, Billington N, Gyimesi M et al (2010) Myosin complexed with ADP and blebbistatin reversibly adopts a conformation resembling the start point of the working stroke. Proc Natl Acad Sci U S A 107:6799–6804. https://doi.org/10.1073/pnas.0907585107
Tan L, Yuan X, Liu Y et al (2019) Non-muscle myosin II: role in microbial infection and its potential as a therapeutic target. Front Microbiol 10:401. https://doi.org/10.3389/fmicb.2019.00401
Terman JR, Kashina A (2013) Post-translational modification and regulation of actin. Curr Opin Cell Biol 25:30–38. https://doi.org/10.1016/J.CEB.2012.10.009
Tobacman LS (2008) Cooperative binding of tropomyosin to actin. Springer, New York, pp 85–94
Tojkander S, Gateva G, Schevzov G et al (2011) A molecular pathway for myosin II recruitment to stress fibers. Curr Biol 21:539–550. https://doi.org/10.1016/j.cub.2011.03.007
Trocóniz IF, Zsolt I, Garrido MJ et al (2006) Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor. Pharm Res 23:1533–1542. https://doi.org/10.1007/s11095-006-0254-1
Trybus KM, Waller GS, Chatman TA (1994) Coupling of ATPase activity and motility in smooth muscle myosin is mediated by the regulatory light chain. J Cell Biol 124:963–969. https://doi.org/10.1083/jcb.124.6.963
Varian K, Tang WHW (2017) Therapeutic strategies targeting inherited cardiomyopathies. Curr Heart Fail Rep 14:321–330. https://doi.org/10.1007/s11897-017-0346-8
Várkuti BH, Képiró M, Horváth IÁ et al (2016) A highly soluble, non-phototoxic, non-fluorescent blebbistatin derivative. Sci Rep 6:26141. https://doi.org/10.1038/srep26141
Verhasselt S, Roman BI, Bracke ME, Stevens CV (2017a) Improved synthesis and comparative analysis of the tool properties of new and existing D-ring modified (S)-blebbistatin analogs. Eur J Med Chem 136:85–103. https://doi.org/10.1016/J.EJMECH.2017.04.072
Verhasselt S, Roman BI, De Wever O et al (2017b) Discovery of (S)-3′-hydroxyblebbistatin and (S)-3′-aminoblebbistatin: polar myosin II inhibitors with superior research tool properties. Org Biomol Chem 15:2104–2118. https://doi.org/10.1039/C7OB00006E
Verhasselt S, Stevens CV, Van den broecke T et al (2017c) Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs. Bioorg Med Chem Lett 27:2986–2989. https://doi.org/10.1016/J.BMCL.2017.05.008
Volkow ND, Morales M (2015) The brain on drugs: from reward to addiction. Cell 162:712–725. https://doi.org/10.1016/J.CELL.2015.07.046
von der Ecken J, Müller M, Lehman W et al (2015) Structure of the F-actin–tropomyosin complex. Nature 519:114–117. https://doi.org/10.1038/nature14033
von der Ecken J, Heissler SM, Pathan-Chhatbar S et al (2016) Cryo-EM structure of a human cytoplasmic actomyosin complex at near-atomic resolution. Nature 534:724–728. https://doi.org/10.1038/nature18295
Wilson IB, Ginsburg S (1955) A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase. Biochim Biophys Acta 18:168–170. https://doi.org/10.1016/0006-3002(55)90040-8
Winder SJ, Ayscough KR (2005) Actin-binding proteins. J Cell Sci 118:651–654. https://doi.org/10.1242/jcs.01670
Winkelmann DA, Forgacs E, Miller MT, Stock AM (2015) Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity. Nat Commun 6:7974. https://doi.org/10.1038/ncomms8974
Wollenberg RD, Taft MH, Giese S et al (2019) Phenamacril is a reversible and noncompetitive inhibitor of Fusarium class I myosin. J Biol Chem 294:1328–1337. https://doi.org/10.1074/jbc.RA118.005408
Wustman BA, Steele JW, Sjoberg ER, Stevens AC (2014) Bringing dead proteins back to life. Elife 3:e02189. https://doi.org/10.7554/eLife.02189
Xiong D, Du Y, Wang H-B et al (2015) Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A 112:11036–11041. https://doi.org/10.1073/pnas.1513359112
Yang Z, Sweeney HL (1995) Restoration of phosphorylation-dependent regulation to the skeletal muscle myosin regulatory light chain. J Biol Chem 270:24646–24649. https://doi.org/10.1074/jbc.270.42.24646
Yoshida H, Cheng W, Hung J et al (2004) Lessons from border cell migration in the Drosophila ovary: a role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A 101:8144–8149. https://doi.org/10.1073/pnas.0400400101
Young E, Briggs S, Miller C (2015) The actin cytoskeleton as a therapeutic target for the prevention of relapse to methamphetamine use. CNS Neurol Disord Drug Targets 14:731–737. https://doi.org/10.2174/1871527314666150529145531
Zhang X, Seftel A, DiSanto ME (2011) Blebbistain, a myosin II inhibitor, as a novel strategy to regulate detrusor contractility in a rat model of partial bladder outlet obstruction. PLoS One 6:e25958. https://doi.org/10.1371/journal.pone.0025958
Zhang C, Chen Y, Yin Y et al (2015) A small molecule species specifically inhibits Fusarium myosin I. Environ Microbiol 17:2735–2746. https://doi.org/10.1111/1462-2920.12711
Zhang H-M, Ji H-H, Ni T et al (2017) Characterization of blebbistatin inhibition of smooth muscle myosin and nonmuscle myosin-2. Biochemistry 56:4235–4243. https://doi.org/10.1021/acs.biochem.7b00311
Acknowledgments
This work was supported by grants from Deutsche Forschungsgemeinschaft to D.J.M (MA1081-22/1) and M.P (PR1478-2/1).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Manstein, D.J., Preller, M. (2020). Small Molecule Effectors of Myosin Function. In: Coluccio, L. (eds) Myosins. Advances in Experimental Medicine and Biology, vol 1239. Springer, Cham. https://doi.org/10.1007/978-3-030-38062-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-38062-5_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-38061-8
Online ISBN: 978-3-030-38062-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)